Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | CTNNB1 | P35222 | 4/20 | 0.38 |
| ▸ | WNT3A | P56704 | 4/20 | 0.38 |
| ▸ | MAP3K14 | Q99558 | 2/20 | 0.37 |
| ▸ | BACE1 | P56817 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17276119 | 0.82 | CTNNB1 (0.46) | PDK2HDAC4CTNNB1WNT3AMAP3K14 | |
| SCHEMBL17276351 | 0.79 | PDK2 (0.44) | PDK2HDAC4BACE1 | |
| SCHEMBL17276575 | 0.78 | PDK2 (0.48) | PDK2HDAC4CTNNB1WNT3AMAPT | |
| SCHEMBL23705407 | 0.70 | MAPT (0.41) | MAP3K14BACE1LMNAMAPTHTT | |
| SCHEMBL12144413 | 0.69 | LMNA (0.43) | MAP3K14BACE1LMNAMAPTHTT | |
| SCHEMBL23704905 | 0.69 | AKR1B1 (0.36) | PDK2MAP3K14LMNAMAPTHTT | |
| SCHEMBL17802125 | 0.69 | MAPT (0.46) | BACE1LMNAMAPTHTTBLM | |
| SCHEMBL14053778 | 0.68 | BACE1 (0.37) | PDK2BACE1LMNAMAPTHTT | |
| SCHEMBL14053726 | 0.68 | BACE1 (0.37) | PDK2BACE1LMNAMAPTHTT | |
| SCHEMBL14053774 | 0.68 | BACE1 (0.37) | PDK2BACE1LMNAMAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3145915-B1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME LLC (US) | 2025-03-19 | — | — | EP | disclosed |
| US-10000454-B2 | Antidiabetic tricyclic compounds | MERCK SHARP & DOHME (US) | 2018-06-19 | — | — | US | disclosed |
| US-20170081287-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME LLC | 2017-03-23 | — | — | US | disclosed |
| WO-2015176267-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2015-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10000454-B2 | Antidiabetic tricyclic compounds | GPR119, GPR65, GPR52 | PDK2 1684/4885HDAC4 549/4885CTNNB1 2520/4885 |
| US-20170081287-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | GPR119, GPR65, GPR52 | PDK2 1684/4885HDAC4 549/4885CTNNB1 2520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.